Search Within

Larry Norton

Formats
  1. Journal Article (411)
  2. Meeting Abstract (297)
  3. Book Section (21)
  4. Conference Paper (16)
  5. Editorial (8)
  6. Guidelines (3)
  7. Correspondence (2)
  8. Miscellaneous (2)
  9. Book Whole (1)
  10. Review (1)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (762)
  2. Breast Medicine Service (762)
  3. Department of Medicine (762)
  4. Solid Tumor Oncology Division (762)
  5. Survivorship Research (393)
  6. GSK Faculty (224)

More Groups

People
  1. Clifford Hudis (293)
  2. Edi Brogi (115)
  3. Andrew Seidman (99)
  4. Sujata Patil (97)
  5. Mark Robson (90)
  6. Hannah Wen (83)

More People

Years
  1. 2025 (9)
  2. 2024 (19)
  3. 2023 (18)
  4. 2022 (16)
  5. 2021 (13)
  6. 2020 (26)

More Years

Publications
  1. Journal of Clinical Oncology (156)
  2. Cancer Research (79)
  3. Breast Cancer Research and Treatment (48)
  4. Clinical Cancer Research (31)
  5. Laboratory Investigation (26)
  6. Modern Pathology (24)

More Publications

Publishers
  1. American Society of Clinical Oncology (160)
  2. American Association for Cancer Research (125)
  3. Nature Publishing Group (77)
  4. Springer (61)
  5. Oxford University Press (50)
  6. Elsevier Inc. (43)

More Publishers

Results (762)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Incidence and severity of sensory neuropathy (SN) with bevacizumab (B) added to dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound (nab) paclitaxel (P) in patients (pts) with early stage breast cancer (BC)
    Meeting Abstract

    Sierecki, M. R.; Rugo, H. S.; McArthur, H. L.; Traina, T. A.; Paulson, M.; Rourke, M.; Norton, L.; Seidman, A. D.; Hudis, C. A.; Dickler, M. N.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Dose-dense (dd) doxorubicin-cyclophosphamide (AC) X 4 and short-term changes in left ventricular ejection fraction (LVEF) alone or with bevacizumab (B) in patients (pts) with early stage breast cancer (BC)
    Meeting Abstract

    Morris, P. G.; Dickler, M. N.; McArthur, H. L.; Traina, T. A.; Nulsen, B.; Steingart, R. M.; Rugo, S.; Norton, L.; Hudis, C. A.; Dang, C. T.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: A phase II study
    Meeting Abstract

    Traina, T. A.; Theodoulou, M.; Dugan, U.; Feigin, K.; Patil, S.; Edwards, C.; Norton, L.; Hudis, C. A.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: Results of CALGB/CTSU 49907
    Meeting Abstract

    Muss, H. B.; Berry, D. L.; Cirrincione, C.; Theodoulou, M.; Mauer, A.; Cohen, H.; Partridge, A. H.; Norton, L.; Hudis, C. A.; Winer, E. P.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Preliminary safety results of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BCA)
    Meeting Abstract

    Dang, C. T.; Lin, N. U.; Lake, D.; Dickler, M. N.; Modi, S.; Seidman, A. D.; Steingart, R. M.; Norton, L.; Winer, E. P.; Hudis, C. A.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • A survey of sleep problems in survivors of breast cancer
    Meeting Abstract

    Passik, S.; Starr, T.; Massie, M. J.; McCabe, M.; Holland, J.; Norton, L.; di Ciccone, B. L.; Li, Y. L.; Reinsel, R.; D'Andrea, G.; more...
    Psycho-Oncology (2008)

    Fulltext@MSK | Save
  • Tanespimycin (17-allylamino-17-demethoxy-geldanamycin; 17-AAG) in breast cancer
    Meeting Abstract

    Modi, S.; Sugarman, S.; Stopeck, A.; Linden, H.; Ma, W.; Chandarlapaty, S.; Solit, D.; Norton, L.; Rosen, N.; Kersey, K.; more...
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • Dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BC): First safety results
    Meeting Abstract

    Dang, C.; Lin, N.; Lake, D.; Theodoulou, M.; Drullinsky, P.; Gorsky, M.; Chen, C.; Norton, L.; Winer, E.; Hudis, C.
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • Racial differences in clinical outcomes from metastatic breast cancer: A pooled analysis of CALGB 9342 and 9840 - Cancer and Leukemia Group B
    Journal Article

    Polite, B. N.; Cirrincione, C.; Fleming, G. F.; Berry, D. A.; Seidman, A.; Muss, H.; Norton, L.; Shapiro, C.; Bakri, K.; Marcom, K.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • The concept of mathematically optimised dose-scheduling as applied to the adjuvant chemotherapy of primary breast cancer: Theory and recent results
    Journal Article

    Norton, L.
    EJC Supplements (2008)

    Fulltext@MSK | Save